Skip to main content
. 2022 Jun 20;226(8):1401–1406. doi: 10.1093/infdis/jiac241

Figure 2.

Figure 2.

Estimated efficacy of UB-612 vaccine after 2 and 3 doses. A model bridging vaccine-induced receptor-binding domain (RBD) immunoglobulin G (IgG) response to vaccine efficacy against symptomatic coronavirus disease 2019 caused by the ancestral Wuhan strain [5]. Estimated efficacy of UB-612 after 2 doses is ∼72% (95% confidence interval [CI], 70%–80%) based on RBD-binding IgG antibodies from 15 participants (phase 1) (geometric mean concentration [GMC], 235 binding antibody units [BAU]/mL [95% CI, 158–350]), ∼82% (95% CI, 80%–85%) based on RBD-binding IgG antibodies from 84 randomly selected phase 2 participants (GMC, 494 BAU/mL [95% CI, 337–725], shown in this graph), and ∼95% (95% CI, 93%–97%) after a booster vaccination (GMC, 6767 [95% CI, 4142–11 057]). Abbreviations: BAU, binding antibody units; GMC, geometric mean concentration; IgG, immunoglobulin G; J+J, Johnson & Johnson; Ox/AZ, Oxford/AstraZeneca; RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization.